敏感驱动基因阳性非小细胞肺癌脑膜转移药物治疗的管理  

Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer

作　　者：陆志琴 蔡婧[1,2] 曾治民 刘安文[1,2] Zhiqin LU;Jing CAI;Zhimin ZENG;Anwen LIU(Department of Oncology,The Second Affiliated of Nanchang University;Jiangxi Key Laboratory of Clinical Translational Cancer Research,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院肿瘤科,南昌330006 [2]江西省肿瘤临床转化重点实验室

出　　处：《中国肺癌杂志》2020年第8期710-718,共9页Chinese Journal of Lung Cancer

基　　金：江西省肿瘤临床转化重点实验室(No.20171BCD40022);江西省研究生创新专项资金项目(No.YC2019-S087);2018 CSCO齐鲁研究基金(No.Y-Q201802-009);2016江西省自然基金项目(No.20161BBG70210)资助。

摘　　要：脑膜转移(leptomeningeal metastasis,LM)是晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)严重并发症之一,虽然发生率不高,但临床症状表现严重,预后差。驱动基因阳性NSCLC较驱动基因阴性患者更容易发生LM。目前,LM的治疗方法主要包括分子靶向治疗、系统化疗、全脑放疗、鞘内化疗及免疫治疗等。尽管治疗手段很多,但LM的疗效仍不令人满意。本文就敏感驱动基因阳性NSCLC LM的药物治疗方面作一综述。Leptomeningeal metastasis(LM)is one of the serious complications of advanced non-small cell lung cancer(NSCLC),although the incidence is not high,the clinical symptoms are severe and the prognosis is poor.LM is prone to occur in patients with positive driver gene than negative.At present,the treatment of LM mainly includes molecular targeted therapy,systemic chemotherapy,whole brain radiotherapy,intrathecal chemotherapy and immunotherapy.Although there are many treatments,the efficacy of LM is still unsatisfactory.This article reviews the drug therapy of sensitive driver gene positive NSCLC LM.

关 键 词：肺肿瘤 脑膜转移 驱动基因阳性 药物治疗 

分 类 号：R734.2[医药卫生—肿瘤]